Regen BioPharma Inc
RGBP · OTCMCIK 1589150fmd_1Z5FN50BPSSKQFYP76KPC1K4SPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2012 to Jun 30, 2026, 55 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Operating income
- (0)
- Net income
- (1)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Operating income
- 0
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +23.5%
- Revenue, 5 yearsFY2020 to FY2025
- +16.5%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Regen BioPharma Inc (RGBP) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $236,561 | $236,560 | 0% | 10-K 2025-12-30 · proof |
| Operating income | -$338,540 | -$417,221 | 10-K 2025-12-30 · proof | |
| Net income | -$1.3 million | -$668,255 | 10-K 2025-12-30 · proof | |
| Cash from operating activities | -$383,591 | -$751,536 | 10-K 2025-12-30 · proof | |
| Total assets | $274,628 | $161,084 | +70.5% | 10-K 2025-12-30 · proof |
| Total liabilities | $6.6 million | $5.4 million | +21.9% | 10-K 2025-12-30 · proof |
| Cash and cash equivalents | $69,555 | $716 | +9,614.4% | 10-K 2025-12-30 · proof |
- What was Regen BioPharma Inc (RGBP)'s revenue in fiscal 2025?
- Regen BioPharma Inc (RGBP) reported revenue of $236,561 for fiscal 2025 (the year ended Sep 30, 2025), against $236,560 the year before (0%). Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
- What was Regen BioPharma Inc (RGBP)'s operating income in fiscal 2025?
- Regen BioPharma Inc (RGBP) reported operating income of -$338,540 for fiscal 2025 (the year ended Sep 30, 2025), against -$417,221 the year before. Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
- What was Regen BioPharma Inc (RGBP)'s net income in fiscal 2025?
- Regen BioPharma Inc (RGBP) reported net income of -$1.3 million for fiscal 2025 (the year ended Sep 30, 2025), against -$668,255 the year before. Source: the 10-K filed with the SEC on Dec 30, 2025 (restated). SEC
- What was Regen BioPharma Inc (RGBP)'s cash from operating activities in fiscal 2025?
- Regen BioPharma Inc (RGBP) reported cash from operating activities of -$383,591 for fiscal 2025 (the year ended Sep 30, 2025), against -$751,536 the year before. Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
- What are Regen BioPharma Inc (RGBP)'s total assets?
- As of Sep 30, 2025, Regen BioPharma Inc (RGBP) reported total assets of $274,628, against $161,084 a year earlier (+70.5%). Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
- What are Regen BioPharma Inc (RGBP)'s total liabilities?
- As of Sep 30, 2025, Regen BioPharma Inc (RGBP) reported total liabilities of $6.6 million, against $5.4 million a year earlier (+21.9%). Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
- What are Regen BioPharma Inc (RGBP)'s cash and cash equivalents?
- As of Sep 30, 2025, Regen BioPharma Inc (RGBP) reported cash and cash equivalents of $69,555, against $716 a year earlier (+9,614.4%). Source: the 10-K filed with the SEC on Dec 30, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RGBP&period_type=annual&limit=5"Information only, not investment advice.